Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 1Neoplasms 1Glioblastoma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3entrectinib 2Radiotherapy 2Proton Therapy 2Fluorodeoxyglucose F18 2FAPI-46 2tipifarnib 1pegvisomant 1fluorodopa F 18 1entinostat 1dactolisib 1alectinib 1Trastuzumab 1Tamoxifen 1Surveys and Questionnaires 1Specimen Handling 1Ritonavir 1Respiratory Therapy 1Radiation Dose Hypofractionation 1Quality of Life 1Protons 1Positron-Emission Tomography 1Photochemotherapy 1Patient Reported Outcome Measures 1Octreotide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Indinavir 1Immunotherapy 1Furosemide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × dactolisib × Endocrine × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡